Frequent Loss of Expression of the Cyclin-Dependent Kinase Inhibitor p27Kip1 in Estrogen-Related Endometrial Adenocarcinomas

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5332-5338

  Masciullo, Valeria ^a   Susini, Tommaso ^c   Zamparelli, Alessandra ^a   Bovicelli, Alessandro ^d   Minimo, Corrado ^a   Massi, Daniela ^c   Taddei, Gianluigi ^c   Maggiano, Nicola ^e   De Iaco, Pierandrea ^d   Ceccaroni, Marcello ^d   Bovicelli, Luciano ^d   Amunni, Gianni ^c   Mancuso, Salvatore ^e   Scambia, Giovanni ^e   Giordano, Antonio ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Temple University   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN; PROTEIN P27;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CYTOPLASM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ATROPHY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTADENOCARCINOMA, SEROUS; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 10744233135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr., 5: 127-156, 1995.
2. Tam, S. W., Shay, J. W., and Pagano, M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16/INK4. Cancer Res., 54: 5816-5820, 1994.
3. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
4. Bullrich, F., MacLachlan, T. K., Sang, N., Druck, T., Veronese, M. L., Allen, S. L., Chiorazzi, N., Koff, A., Heubner, K. Croce, C. M., and Giordano, A. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, PITALRE and a cdk inhibitor, p27kipl, to regions involved in human cancer. Cancer Res., 55: 1199-1205, 1995.
5. Slingerland, J., and Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol., 183: 10-17, 2000.
6. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC), 269: 682-685, 1995.
7. FIGO. FIGO news. Int. J. Gynecol. Obstet., 28: 189-193, 1989.
8. Mariani, A., Sebo, T. J., Katzmann, J. A., Keeney, G. L., Roche, P. C., Lesnick, T. G., and Podratz, K. C. Pretreatment assessment of prognostic indicators in endometrial cancer. Am. J. Obstet. Gynecol., 182: 1535-1544, 2000.
9. Santin, A. D., Bellone, S., Gokden, M., Palmieri, M., Dunn, D., Agha, J., Roman, J. J., Hutchins, L., Pecorelli, S., O'Brien, T., Cannon, M. J., and Parham, G. P. Overexpression of her-2/neu in uterine serous papillary cancer. Clin, Cancer Res., 8: 1271-1279, 2002.
10. Geisler, J. P., Geisler, H. E., Wiemann, M. C., Zhou, Z., Miller, G. A., and Crabtree, W. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol. Oncol., 71: 305-307, 1998.
11. Susini, T., Baldi, F., Howard, C. M., Baldi, A., Taddei, G., Massi, D., Rapi, S., Savino, L, Massi, G., and Giordano, A. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J. Clin. Oncol., 16: 1085-1093, 1998.
12. Susini, T., Rapi, S., Savino, L., Boddi, V., Berti, P., and Massi, G. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am. J. Obstet Gynecol, 170: 527-534, 1994.
13. Geisler, J. P., Wiemann, M. C., Zhou, Z., Miller, G. A., and Geisler, H. E. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol. Oncol., 61: 373-377, 1996.
14. Heffner, H. M., Freedman, A. N., Asirwatham, J. E., and Lele, S. B. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial endocarcinoma. Eur. J. Gynaecol. Oncol., 20: 8-12. 1999.
15. Catzavelos, C., Bhattacharya, N., Ung, Y., Wilson, J., Roncari, L., Sandhu, C., Shaw. P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K., and Slingerland, J. Decreased levels of the cell cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
16. Porter, P., Malone. K., Haegerty, G., Alexander, G., Gatti, L., Firpo, E., Daling, J., and Roberts, J. Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
17. Huang, L. W., Chao, S. L., Hwang, J. L., and Chou. Y. Y. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol. Oncol., 85: 524-528, 2002.
18. Masciullo, V., Sgambato, A., Pacilio, C., Pucci, B., Ferrandina, G. Palazzo, J., Carbone, A., Cittadini, A., Mancuso, S., Scambia, G., and Giordano, A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res., 59: 3790-3794, 1999.
19. Masciullo, V., Ferrandina, G., Pucci, B., Fanfani, F., Lovergine, S. Palazzo, J., Zannoni, G., Mancuso, S., Scambia, G., and Giordano, A p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin. Cancer Res., 6: 4816-4822, 2000.
20. Bamberger, A. M., Riethdorf, L. Milde-Langosch, K., Bamberger C. M., Thuneke, I., Erdmann, I., Schulte, H. M., and Loning, T. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch., 434: 423-428, 1999.
21. Ahn, H. J., Kwon, W. K., Choi, Y., and Cho, N. H. Expression of cyclin E and cyclin dependent kinase inhibitor p27kip1 in uterine endometrial carcinoma: relationship with p53 status. Int. J. Surg. Pathol., 6 205-212, 1998.
22. Schmitz, M. J., Hendricks, D. T., Farley, J., Taylor, R. R., Geradts, J., Rose, G. S., and Birrer, M. J. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol. Oncol., 77: 439-445, 2000.
23. Nycum, L. R., Smith, L. M., Farley, J. H., Kost, E. R., Method, M. W., and Birrer, M. J. The role of p27 in endometrial carcinoma. Gynecol. Oncol., 81: 242-246, 2001.
24. Watanabe, J., Sato, H., Kanai. T., Kamata, Y., Jobo, T., Hata, H., Fujisawa, T., Ohno, E., Kameya, T., and Kuramoto, H. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus-correlation with proliferation and clinicopathological parameters. Br. J. Cancer., 87: 81-85, 2002.
25. Sgambato, A., Cittadini, A., Faraglia, B., and Weinstein, I. B. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J. Cell Physiol., 183: 18-27, 2000.
26. Hori, M., Takechi, K., Arai, Y., Yomo, H., Itabashi, M., Shimazaki, J., Inagawa, S., and Hori, M. Comparison of macroscopic appearance and estrogen receptor-α regulators after gene alteration in human endometrial cancer. Int. J. Gynecol. Cancer, 10: 469-476, 2000.
27. Demopoulos, R. I., Mesia, A. F., Mittal, K., and Vamvakas, E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int. J. Gynecol. Pathol., 18: 233-237, 1999.
28. Susini, T., Massi, D., Paglierini, M., Masciullo, V., Scambia, G., Giordano, A., Alunni, G., Massi, G., and Taddei, G. L. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum. Pathol., 32: 360-367, 2001.
29. Kiyokawa, H., Kineman, R., Manova-Todorova, K., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27kip1. Cell, 85: 721-732, 1996.
30. Fero, M., Rivkin, M., Tasch, M., Porter, P., Carow, C., Firpo, E., Tsai, L., Broudy, V., Perlmutter, R., Kaushansky, K., and Roberts, J. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27kip1 deficient mice. Cell, 85: 733-744, 1996.
31. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., and Nakayama, K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
32. Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., and Kemp, C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (Lond.), 396: 177-180, 1998.
33. Ponce-Castaneda, M. V., Lee, M. H., Latres. E., Polyak, K., Lacombe, L., Montgomery, K., Mathew. S., Krauter, K., Sheinfeld, J., Massague, J., et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human minors. Cancer Res., 55: 1211-1214, 1995.
34. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano. M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
35. Singh, S. P., Lipman, J., Goldman, H., Ellis, F. H., Aizenman, L., Cangi, M. G., Signoretti, S., Chiaur, D. S., Pagano, M., and Loda, M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res., 5: 1730-1735, 1998.
36. Gunther, K., Jung, A., Volker. U., Meyer, M., Brabletz, T., Matzel, K. E., Reymond, M. A., Kirchner, T., and Hohenberger, W. p27(kip1) expression in rectal cancer correlates with disease-free survival. J. Surg. Res., 92: 78-84, 2000.
37. Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem., 277: 14355-14358, 2002.
38. Tomoda, K., Kubota, Y., and Kato, J. Degradation of the cyclin-dependent-kinase inhibitor p27 kip1 is instigated by Jabl. Nature (Lond.), 398: 160-165, 1999.
39. Fujita, N., Sato, S., Katayama, K., and Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem., 277: 28706-28713, 2002.